Biopharmaceutical company Nuvalent, Inc. (NUVL) announced Thursday that Henry Pelish has been promoted to Chief Scientific Officer. In this role, Pelish will continue to oversee discovery and early-stage development activities. He currently serves as Senior Vice President, Drug Discovery.
Pelish contributed to the creation of Nuvalent and joined as Biology lead in 2018, overseeing the discovery and early-stage development of zidesamtinib, NVL-655 and NVL-330 and ongoing research and discovery efforts.
Prior to joining Nuvalent, Pelish was a group leader in the laboratory of Professor Matthew Shair at Harvard University.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.